Frontier Medicines Corp. has announced the selection of FMC-220, a first-in-class covalent small-molecule activator of p53 Y220C designed to address potency and tolerability challenges of noncovalent ...

New research suggests a genetic mutation previously believed to promote esophageal cancer might actually play a protective ...

FMC-220 is a first-in-class covalent activator of p53Y220Cdesigned to address potency and tolerability challenges of non-covalent approachesIn ...

p53 is often referred to as the “guardian of the genome” due to its critical role in maintaining genomic stability, but it can be altered in cancer with mutations such as Y220C. The Y220C ...

Discover recent research that sheds light on a promising therapeutic strategy for tackling prostate cancer by targeting the ...

A genetic fault long believed to drive the development of esophageal cancer may in fact play a protective role early in the disease, according to new research published in Nature Cancer.

A genetic fault long believed to drive the development of esophageal cancer may in fact play a protective role early in the disease. This unexpected discovery could help doctors identify which ...

A surprising discovery reveals that a gene previously thought to accelerate esophageal cancer actually helps protect against it initially. This pivotal study could lead to better prediction and ...

Mutation or dysregulation of tumour-suppressor ... The binding of a DARPin to p53 displaces the human papillomavirus (HPV) E6 protein and stabilizes p53 in HPV-infected cells.